Abbott Laboratories 8-K

PositiveEarningsGuidance raisedImpairment / chargeLegal / investigation

Exact Sciences acquisition boosted reported Diagnostics growth; Abbott raised its FY2026 adjusted EPS outlook.

Filed 2026-07-16 07:36 ET

Summary

Q2 2026 results with Q3 and FY2026 guidance. Abbott reported sales growth of 13.0%, while comparable sales growth was 4.8%; the Exact Sciences acquisition contributed to the gap. GAAP earnings fell, while adjusted earnings increased; Abbott raised its FY2026 adjusted EPS range and reaffirmed comparable sales growth guidance.

Key Figures

Metric Q2 2026 Q2 2025 Y/Y
Net sales $12.6B $11.1B 13.0%
Operating earnings, GAAP $1.69B $2.05B (17.5%)
Net earnings, GAAP $928M $1.78B (47.8%)
Net earnings, non-GAAP $2.29B $2.21B 3.5%
Diluted EPS, GAAP $0.53 $1.01 n/m
Diluted EPS, adjusted non-GAAP $1.31 $1.26 4.0%
  • Comparable sales growth was 4.8%. Diagnostics sales grew 42.3% reported but 2.9% comparable, reflecting the Exact Sciences acquisition; Medical Devices grew 8.4% comparable, while Nutrition declined 3.6%.
  • Q2 net earnings excluded $1.362B of after-tax specified charges ($0.78 per share), including $658M of intangible amortization. Specified items included $385M of legal reserves related to an agreed-in-principle settlement, subject to contingencies.
  • Abbott returned $2.1B to shareholders through dividends and share repurchases. It declared a $0.63-per-share quarterly dividend.

Guidance

Metric Period Guidance Prior Direction
Comparable sales growth FY2026 6.5%-7.5% 6.5%-7.5% reaffirmed
Adjusted diluted EPS, non-GAAP FY2026 $5.45-$5.60 $5.38-$5.58 raised
Adjusted diluted EPS, non-GAAP Q3 2026 $1.38-$1.46 — —

Investor Takeaways

  • Q3 results and comparable-sales trends will indicate whether Abbott’s expected second-half sales and earnings acceleration is materializing.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback